Dual Antiplatelet Therapy and Heparin "Bridging" Significantly Increase the Risk of Bleeding Complications After Pacemaker or Implantable Cardioverter-Defibrillator Device Implantation

Christine Tompkins, Alan Cheng, Darshan Dalal, Jeffrey A. Brinker, Charles T. Leng, Joseph E. Marine, Saman Nazarian, David D. Spragg, Sunil Sinha, Henry Halperin, Gordon F. Tomaselli, Ronald D. Berger, Hugh Calkins, Charles Henrikson

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Objectives: This study was designed to assess the risk of significant bleeding complications in patients receiving antiplatelet or anticoagulation medications at the time of implantable cardioverter-defibrillator (ICD) device implantation. Background: Periprocedural management of antiplatelet or anticoagulation therapy at the time of device implantation remains controversial. Methods: We performed a retrospective chart review of bleeding complications in all patients undergoing ICD or pacemaker implantation from August 2004 to August 2007. Aspirin or clopidogrel use was defined as taken within 5 days of the procedure. A significant bleeding complication was defined as need for pocket exploration or blood transfusion; hematoma requiring pressure dressing or change in anticoagulation therapy; or prolonged hospitalization. Results: Of the 1,388 device implantations, 71 had bleeding complications (5.1%). Compared with controls not taking antiplatelet agents (n = 255), the combination of aspirin and clopidogrel (n = 139) significantly increased bleeding risk (7.2% vs. 1.6%; p = 0.004). In patients taking aspirin alone (n = 536), bleeding risk was marginally higher than it was for patients taking no antiplatelet agents (3.9% vs. 1.6%, p = 0.078). The use of periprocedural heparin (n = 154) markedly increased risk of bleeding when compared with holding warfarin until the international normalized ratio (INR) was normal (n = 258; 14.3% vs. 4.3%; p <0.001) and compared with patients receiving no anticoagulation therapy (14.3% vs.1.6%; p <0.0001). There was no statistical difference in bleeding risk between patients continued on warfarin with an INR ≥1.5 (n = 46) and patients who had warfarin withheld until the INR was normal (n = 258; 6.5% vs. 4.3%; p = 0.50). Conclusions: Dual antiplatelet therapy and periprocedural heparin significantly increase the risk of bleeding complications at the time of pacemaker or ICD implantation.

Original languageEnglish (US)
Pages (from-to)2376-2382
Number of pages7
JournalJournal of the American College of Cardiology
Volume55
Issue number21
DOIs
StatePublished - May 25 2010
Externally publishedYes

Fingerprint

Implantable Defibrillators
Heparin
Hemorrhage
Equipment and Supplies
clopidogrel
International Normalized Ratio
Warfarin
Aspirin
Therapeutics
Platelet Aggregation Inhibitors
Bandages
Blood Transfusion
Hematoma
Hospitalization
Pressure

Keywords

  • anticoagulation
  • antiplatelet
  • complications
  • defibrillator
  • pacemaker

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Dual Antiplatelet Therapy and Heparin "Bridging" Significantly Increase the Risk of Bleeding Complications After Pacemaker or Implantable Cardioverter-Defibrillator Device Implantation. / Tompkins, Christine; Cheng, Alan; Dalal, Darshan; Brinker, Jeffrey A.; Leng, Charles T.; Marine, Joseph E.; Nazarian, Saman; Spragg, David D.; Sinha, Sunil; Halperin, Henry; Tomaselli, Gordon F.; Berger, Ronald D.; Calkins, Hugh; Henrikson, Charles.

In: Journal of the American College of Cardiology, Vol. 55, No. 21, 25.05.2010, p. 2376-2382.

Research output: Contribution to journalArticle

Tompkins, C, Cheng, A, Dalal, D, Brinker, JA, Leng, CT, Marine, JE, Nazarian, S, Spragg, DD, Sinha, S, Halperin, H, Tomaselli, GF, Berger, RD, Calkins, H & Henrikson, C 2010, 'Dual Antiplatelet Therapy and Heparin "Bridging" Significantly Increase the Risk of Bleeding Complications After Pacemaker or Implantable Cardioverter-Defibrillator Device Implantation', Journal of the American College of Cardiology, vol. 55, no. 21, pp. 2376-2382. https://doi.org/10.1016/j.jacc.2009.12.056
Tompkins, Christine ; Cheng, Alan ; Dalal, Darshan ; Brinker, Jeffrey A. ; Leng, Charles T. ; Marine, Joseph E. ; Nazarian, Saman ; Spragg, David D. ; Sinha, Sunil ; Halperin, Henry ; Tomaselli, Gordon F. ; Berger, Ronald D. ; Calkins, Hugh ; Henrikson, Charles. / Dual Antiplatelet Therapy and Heparin "Bridging" Significantly Increase the Risk of Bleeding Complications After Pacemaker or Implantable Cardioverter-Defibrillator Device Implantation. In: Journal of the American College of Cardiology. 2010 ; Vol. 55, No. 21. pp. 2376-2382.
@article{860a3f2cb3fa43f992a30160629a234a,
title = "Dual Antiplatelet Therapy and Heparin {"}Bridging{"} Significantly Increase the Risk of Bleeding Complications After Pacemaker or Implantable Cardioverter-Defibrillator Device Implantation",
abstract = "Objectives: This study was designed to assess the risk of significant bleeding complications in patients receiving antiplatelet or anticoagulation medications at the time of implantable cardioverter-defibrillator (ICD) device implantation. Background: Periprocedural management of antiplatelet or anticoagulation therapy at the time of device implantation remains controversial. Methods: We performed a retrospective chart review of bleeding complications in all patients undergoing ICD or pacemaker implantation from August 2004 to August 2007. Aspirin or clopidogrel use was defined as taken within 5 days of the procedure. A significant bleeding complication was defined as need for pocket exploration or blood transfusion; hematoma requiring pressure dressing or change in anticoagulation therapy; or prolonged hospitalization. Results: Of the 1,388 device implantations, 71 had bleeding complications (5.1{\%}). Compared with controls not taking antiplatelet agents (n = 255), the combination of aspirin and clopidogrel (n = 139) significantly increased bleeding risk (7.2{\%} vs. 1.6{\%}; p = 0.004). In patients taking aspirin alone (n = 536), bleeding risk was marginally higher than it was for patients taking no antiplatelet agents (3.9{\%} vs. 1.6{\%}, p = 0.078). The use of periprocedural heparin (n = 154) markedly increased risk of bleeding when compared with holding warfarin until the international normalized ratio (INR) was normal (n = 258; 14.3{\%} vs. 4.3{\%}; p <0.001) and compared with patients receiving no anticoagulation therapy (14.3{\%} vs.1.6{\%}; p <0.0001). There was no statistical difference in bleeding risk between patients continued on warfarin with an INR ≥1.5 (n = 46) and patients who had warfarin withheld until the INR was normal (n = 258; 6.5{\%} vs. 4.3{\%}; p = 0.50). Conclusions: Dual antiplatelet therapy and periprocedural heparin significantly increase the risk of bleeding complications at the time of pacemaker or ICD implantation.",
keywords = "anticoagulation, antiplatelet, complications, defibrillator, pacemaker",
author = "Christine Tompkins and Alan Cheng and Darshan Dalal and Brinker, {Jeffrey A.} and Leng, {Charles T.} and Marine, {Joseph E.} and Saman Nazarian and Spragg, {David D.} and Sunil Sinha and Henry Halperin and Tomaselli, {Gordon F.} and Berger, {Ronald D.} and Hugh Calkins and Charles Henrikson",
year = "2010",
month = "5",
day = "25",
doi = "10.1016/j.jacc.2009.12.056",
language = "English (US)",
volume = "55",
pages = "2376--2382",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "21",

}

TY - JOUR

T1 - Dual Antiplatelet Therapy and Heparin "Bridging" Significantly Increase the Risk of Bleeding Complications After Pacemaker or Implantable Cardioverter-Defibrillator Device Implantation

AU - Tompkins, Christine

AU - Cheng, Alan

AU - Dalal, Darshan

AU - Brinker, Jeffrey A.

AU - Leng, Charles T.

AU - Marine, Joseph E.

AU - Nazarian, Saman

AU - Spragg, David D.

AU - Sinha, Sunil

AU - Halperin, Henry

AU - Tomaselli, Gordon F.

AU - Berger, Ronald D.

AU - Calkins, Hugh

AU - Henrikson, Charles

PY - 2010/5/25

Y1 - 2010/5/25

N2 - Objectives: This study was designed to assess the risk of significant bleeding complications in patients receiving antiplatelet or anticoagulation medications at the time of implantable cardioverter-defibrillator (ICD) device implantation. Background: Periprocedural management of antiplatelet or anticoagulation therapy at the time of device implantation remains controversial. Methods: We performed a retrospective chart review of bleeding complications in all patients undergoing ICD or pacemaker implantation from August 2004 to August 2007. Aspirin or clopidogrel use was defined as taken within 5 days of the procedure. A significant bleeding complication was defined as need for pocket exploration or blood transfusion; hematoma requiring pressure dressing or change in anticoagulation therapy; or prolonged hospitalization. Results: Of the 1,388 device implantations, 71 had bleeding complications (5.1%). Compared with controls not taking antiplatelet agents (n = 255), the combination of aspirin and clopidogrel (n = 139) significantly increased bleeding risk (7.2% vs. 1.6%; p = 0.004). In patients taking aspirin alone (n = 536), bleeding risk was marginally higher than it was for patients taking no antiplatelet agents (3.9% vs. 1.6%, p = 0.078). The use of periprocedural heparin (n = 154) markedly increased risk of bleeding when compared with holding warfarin until the international normalized ratio (INR) was normal (n = 258; 14.3% vs. 4.3%; p <0.001) and compared with patients receiving no anticoagulation therapy (14.3% vs.1.6%; p <0.0001). There was no statistical difference in bleeding risk between patients continued on warfarin with an INR ≥1.5 (n = 46) and patients who had warfarin withheld until the INR was normal (n = 258; 6.5% vs. 4.3%; p = 0.50). Conclusions: Dual antiplatelet therapy and periprocedural heparin significantly increase the risk of bleeding complications at the time of pacemaker or ICD implantation.

AB - Objectives: This study was designed to assess the risk of significant bleeding complications in patients receiving antiplatelet or anticoagulation medications at the time of implantable cardioverter-defibrillator (ICD) device implantation. Background: Periprocedural management of antiplatelet or anticoagulation therapy at the time of device implantation remains controversial. Methods: We performed a retrospective chart review of bleeding complications in all patients undergoing ICD or pacemaker implantation from August 2004 to August 2007. Aspirin or clopidogrel use was defined as taken within 5 days of the procedure. A significant bleeding complication was defined as need for pocket exploration or blood transfusion; hematoma requiring pressure dressing or change in anticoagulation therapy; or prolonged hospitalization. Results: Of the 1,388 device implantations, 71 had bleeding complications (5.1%). Compared with controls not taking antiplatelet agents (n = 255), the combination of aspirin and clopidogrel (n = 139) significantly increased bleeding risk (7.2% vs. 1.6%; p = 0.004). In patients taking aspirin alone (n = 536), bleeding risk was marginally higher than it was for patients taking no antiplatelet agents (3.9% vs. 1.6%, p = 0.078). The use of periprocedural heparin (n = 154) markedly increased risk of bleeding when compared with holding warfarin until the international normalized ratio (INR) was normal (n = 258; 14.3% vs. 4.3%; p <0.001) and compared with patients receiving no anticoagulation therapy (14.3% vs.1.6%; p <0.0001). There was no statistical difference in bleeding risk between patients continued on warfarin with an INR ≥1.5 (n = 46) and patients who had warfarin withheld until the INR was normal (n = 258; 6.5% vs. 4.3%; p = 0.50). Conclusions: Dual antiplatelet therapy and periprocedural heparin significantly increase the risk of bleeding complications at the time of pacemaker or ICD implantation.

KW - anticoagulation

KW - antiplatelet

KW - complications

KW - defibrillator

KW - pacemaker

UR - http://www.scopus.com/inward/record.url?scp=77952217479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952217479&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2009.12.056

DO - 10.1016/j.jacc.2009.12.056

M3 - Article

VL - 55

SP - 2376

EP - 2382

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 21

ER -